Madri­gal’s NASH drug wins on piv­otal PhI­II end­points, set­ting stage for ac­cel­er­at­ed ap­proval

Madri­gal Phar­ma­ceu­ti­cals says its NASH drug, resme­tirom, has met its ear­ly end­points in a Phase III tri­al, mark­ing a ma­jor suc­cess in a field lit­tered with fail­ures in re­cent years. Now, the com­pa­ny plans to sub­mit for ac­cel­er­at­ed ap­proval in the first half of next year, CEO Paul Fried­man said in a state­ment.

The biotech’s stock $MDGL was up over 200% in pre-mar­ket trad­ing, eclips­ing the $200 mark. It had closed at just un­der $64 on Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER